First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer.
OBJECTIVE
To evaluate the long-term efficacy of high-intensity focused ultrasound (HIFU) therapy for patients with localised prostate cancer.


METHODS
Patients included in this multicentre analysis had T1-T2 NxM0 prostate cancer, a PSA<15 ng/ml, and a Gleason score (GS) < or = 7, and were treated with prototypes or first-generation Ablatherm HIFU devices between October 1997 and August 2001. The Phoenix definition of biochemical failure was used (PSA nadir+2). Treatment failure was defined as: biochemical failure or positive biopsy.


RESULTS
A total of 140 patients with a mean (SD) age 69.1 yr (6.6) were included. Mean (SD) follow-up was 6.4 yr (1.1). Control prostate biopsies were negative in 86.4% of patients. Median PSA nadir of 0.16 ng/ml (range, 0.0-9.1) was achieved at a mean (SD) of 4.9 mo (5.2). A PSA nadir < or = 0.5 ng/ml was recorded in 68.4% of patients. The actuarial biochemical failure-free survival rates (SR) at 5 and 7 yr were 77% and 69%, respectively. The actuarial disease-free SR at 5 and 7 yr were 66% and 59%, respectively.


CONCLUSIONS
This study demonstrates the effective long-term cancer control achieved with HIFU in patients with low- or intermediate-risk localised prostate cancer.
Blana
Andreas
A
Department of Urology, University of Regensburg, St Josef Hospital, Regensburg, Germany. blana@caritasstjosef.de <blana@caritasstjosef.de>
Murat
François J
FJ
Walter
Bernhard
B
Thuroff
Stefan
S
Wieland
Wolf F
WF
Chaussy
Christian
C
Gelet
Albert
A
D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D013997:Time Factors; D036761:Ultrasound, High-Intensity Focused, Transrectal